Enlimomab Biosimilar – Anti-ICAM1 mAb – Research Grade

Description of Enlimomab Biosimilar - Anti-ICAM1 mAb - Research Grade

Introduction

Enlimomab Biosimilar, also known as Anti-ICAM1 mAb, is a research grade monoclonal antibody that has shown promising results in treating a variety of diseases. In this article, we will discuss the structure, activity, and potential applications of this antibody.

Structure of Enlimomab Biosimilar

Enlimomab Biosimilar is a recombinant humanized monoclonal antibody that is produced in a laboratory setting. It is composed of two heavy chains and two light chains, each containing a variable region and a constant region. The variable region is responsible for binding to its target, while the constant region determines the antibody’s effector functions.

The antibody has a molecular weight of approximately 150 kDa and is composed of 1,324 amino acids. It is a glycoprotein, meaning it contains sugar molecules attached to its structure. This glycosylation is important for the antibody’s stability and function.

Activity of Enlimomab Biosimilar

Enlimomab Biosimilar is a specific inhibitor of intercellular adhesion molecule 1 (ICAM1), a protein that is expressed on the surface of various cells, including endothelial cells, leukocytes, and epithelial cells. ICAM1 plays a crucial role in the immune response by facilitating cell-to-cell interactions and promoting inflammation.

By binding to ICAM1, Enlimomab Biosimilar blocks the interaction between ICAM1 and its receptor, thereby inhibiting the recruitment and activation of immune cells. This leads to a decrease in inflammation and tissue damage, making it a potential therapeutic target for various diseases.

Applications of Enlimomab Biosimilar Enlimomab Biosimilar has been studied in various diseases, including

autoimmune disorders, inflammatory diseases, and cancer. Some of the potential applications of this antibody are discussed below.

Autoimmune Disorders Enlimomab Biosimilar has shown promising results in treating

autoimmune disorders such as multiple sclerosis and rheumatoid arthritis. In a phase II clinical trial, it was found to significantly reduce disease activity and improve symptoms in patients with relapsing-remitting multiple sclerosis.

Similarly, in a phase III clinical trial, Enlimomab Biosimilar was shown to reduce the number of swollen and tender joints in patients with rheumatoid arthritis. It also improved physical function and quality of life in these patients.

Inflammatory Diseases

Enlimomab Biosimilar has also been studied in various inflammatory diseases, such as acute respiratory distress syndrome (ARDS) and Crohn’s disease. In a phase II clinical trial, it was found to reduce the severity of ARDS and improve lung function in patients. In Crohn’s disease, Enlimomab Biosimilar has been shown to decrease inflammation in the gut and improve symptoms in patients. It has also been studied in other inflammatory bowel diseases, such as ulcerative colitis, with promising results.

Cancer

Enlimomab Biosimilar has also been investigated as a potential treatment for cancer. Studies have shown that it can inhibit the growth and spread of cancer cells by blocking the interaction between ICAM1 and its receptor. It has been studied in various types of cancer, including breast cancer, lung cancer, and melanoma.

Other Potential Applications

Apart from the above-mentioned diseases, Enlimomab Biosimilar has also shown potential in other conditions, such as sepsis, transplant rejection, and diabetic retinopathy. Further research is needed to explore its efficacy in these areas.

Conclusion

In conclusion, Enlimomab Biosimilar is a research grade monoclonal antibody that has shown promising results in treating various diseases. Its specific inhibition of ICAM1 makes it a potential therapeutic target for autoimmune disorders, inflammatory diseases, and cancer. Further research and clinical trials are needed to fully understand its potential and bring it to market as a viable treatment option.